ReaLi Tide Biological Technology (Weihai) Co., Ltd. (hereinafter referred to as "RLTBIO") was established in May 2016 and is located Shandong Province. It is an innovative enterprise dedicated to the research and development, production, and sales of high-tech pharmaceutical and medical beauty products, mainly engaged in the production and sales of raw materials, active pharmaceutical ingredients, and formulations for peptides, proteins, polysaccharides, nucleic acids, and marine biotechnology products; Technological development, production, and operation of medical devices, health foods, and cosmetics.
In the realm of cosmetic and aesthetic ingredients derived from nucleic acids, peptides, and polysaccharides, RLTBIO has secured Ingredient Filing Codes for over 400 cosmetic active ingredients, with continuous updates ongoing. The company has developed pioneering medical aesthetic ingredients, including:PDRN (Nucleic Acid), Type III Human Recombinant Collagen, Sodium Ascorbylpropyl Hyaluronate (Polysaccharide): Recipient of the 2023 ICIC Award for Innovative Cosmetic Ingredients, All-Trans Retinyl Hyaluronate: China-exclusive, Acetylated Hyaluronic Acid, Cationic Hyaluronic Acid, Functional Peptides: For cosmetic applications, with several products being domestically exclusive.
RLTBIO is a biopharmaceutical enterprise that possessesadvanced solid-phase synthesis technoloay for biopeptides and research and development production technology folDiopolysacharides, t ha a hioh industry reputaion andinluence inthe biopepidesindustny, and has won honors such as national high-tech enterprise,technology onented smal andmedium-sized enterprise recoanized by the Ministry of scdience and Technology, "Gazele" enterise in Shandong Provincein 2022. "specialized.Refined. Unigue and New smalandmedum-sized enteruse in shandono rovncein 202.vice chaian wnit othe aoide branch othe ist china biopharmaceuicalnousioy Asadaton excelent enterisein the arowthgroup ofthe 8th china lnnovation and Entrepreneurship Competion in 2019,the most arowing enterpnse in the top 10 pharmaceuicalintenationazation enterorisesin 2019.the winninenterprise in the Shandong division of the 9th China Innovation and Entrepreneurship Competition in 2020.and the maior project enterprise selected for the conversion of old and newkinetic energyin Shandong Province. Title, thas growm into thelargest production base for biological peptides and bioloaical nuceic acid raw matenials in northern China.and is also atrusted global CRO&CDiMO one-stop comprehensive service provider for peptides, as well as an excelent partner empowerment platform
RLTBIO is located in Nanhai New District, Weihai City, Shandong Province, covering a total area of 250,000 m2. The facility comprises over 20,000 m2 of constructed space with a cumulative investment exceeding RMB 300 million. Current operational infrastructure includes a 3,000 m² R&D center and cGMP-compliant pilot base; a 10,000 m² API workshop; a 2,000 m² plant building with 700 m² clean area; a 1,000 m² power station; warehouses and sewage treatment facilities; and a 6,600 m² office building.
Additionally, RLTBIO operates a 1,040 m² preparation workshop housing freeze-dried powder injection and small-volume injection production lines, primarily manufacturing peptide and polysaccharide preparations.The company maintains a registered capital of RMB 58.0622 million, with total assets of RMB 306.9224 million and net assets of RMB 227.7011 million. RLTBIO employs 180 staff, including R&D personnel constituting over 43% of the total workforce, 7 PhD holders, and 7 technical leaders (including 2 academic leaders) featuring 3 Shandong "Taishan Industry Leading Talents" and 2 Weihai-specialized overseas experts. Among R&D personnel, 17 hold senior or intermediate technical titles, representing 21.79% of this team. This talent pool forms an internationally competitive R&D team with core independent IP rights and exceptional technical execution.
RLTBIO holds five provincial-level innovation platforms: the Shandong Province Marine Biological Nucleic Acid Health Materials Engineering Technology Collaborative Innovation Center; the Shandong Province Biopeptide Engineering Research Center; the Shandong Province One Enterprise One Technology R&D Center; and the Shandong Province Technology Center.
The company has executed over 30 major scientific projects, including 1 national and 6 provincial initiatives, with the national project rated "Excellent" upon acceptance. The current IP portfolio includes 20 authorized invention patents, 30 utility model patents, and 20 invention patents under review. RLTBIO's new high-end preparation workshop utilizes self-developed APIs and advanced transdermal technologies such as nano, liposome, and microsphere systems to manufacture specialized premium cosmetic products.
Copyright © ReaLi Tide Biological Technology ( Weihai ) Co.,Ltd. Some images and text are sourced from the internet. If there is any infringement, please contact us for removal.
